Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CGC

Pharma Buy, Hold, or Sell: 4 Stocks Worth Considering

The pharmaceutical industry is anticipated to thrive as demand grows and technology advances. However, given the macroeconomic uncertainties, let us analyze leading pharma stocks Zoetis (ZTS), Verano Holding (VRNOF), Canopy Growth (CGC) and SNDL (SNDL) to identify whether they are a Buy, Hold, or Sell. Read on.

StockNews.com

Cannabis Check: Should You Consider Canopy Growth (CGC) and Tilray (TLRY) for Your 2024 Portfolio?

The cannabis industry is undergoing a turbulent time due to legalization troubles and its struggles to realize gains. Amid this, would it be wise to invest in Tilray Brands (TLRY) and Canopy Growth (CGC) this year? Keep reading….

StockNews.com

Rare copy of The Amazing Spider-Man No 1 sells for more than £1m

The record price was set by one of only two copies rated near mint/mint in an auction alongside issues of Superman No 1 and All-Star Comics No 8 which featured Wonder Woman’s first appearance

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Struggling Stocks to Skip After Reverse Splits

These two beaten-down stocks just climbed out of the penny stock basement, but they're still not the best names to buy for investors looking to speculate on upside in the EV and cannabis industries.

Barchart

Speculator Alert: Canopy Growth (CGC) May Live Up to Its Name

While practically every indicator out there suggests CGC stock is a market idea to dump right away, the options arena suggests otherwise.

Barchart

3 Cannabis Stocks Analysts Like Better Than Canopy Growth

Discover three cannabis stocks with significant growth potential, and learn why analysts favor these names over Canopy Growth.

Barchart

What Lies Ahead for SNDL Inc. (SNDL) and Canopy Growth (CGC)?

The cannabis industry is undergoing a turbulent time due to legalization troubles and its struggles to realize gains. Amid this, would it be wise to invest in SNDL Inc. (SNDL) and Canopy Growth (CGC) now? Keep reading….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Cannabis Stocks That Have More Upside Potential Than Canopy Growth, According to Wall Street Analysts

CGC has nearly tripled since late August - and now these three marijuana stocks have more upside potential, according to Wall Street.

Barchart

What Should Pharma Investors Plan to Do With Canopy Growth (CGC) this Month?

Canadian cannabis producer Canopy Growth (CGC) reiterated ongoing concerns about its loss-making status. While the company is making significant efforts to return to profitability, is the stock worth buying now? Read on.

StockNews.com

Canopy Growth (CGC) vs. Collegium Pharmaceutical (COLL): Which Pharma Stock Is the Better Buy for Growth Investors?

The pharma industry is poised for long-term growth supported by increasing demand for drugs worldwide and technological advancements. While leading pharma stocks Collegium Pharmaceutical (COLL) and Canopy Growth (CGC) should benefit from the industry tailwinds, let us determine which is the better buy.

StockNews.com

‘It’s fun to cook up the stupidest idea’: the people competing to make the worst computer games possible

The annual Crap Games Competition has been bringing Spectrum fans together for more than 25 years. It all began with an April fool’s joke in a magazine called Your Sinclair …

The Guardian - UK

Buy, Hold or Sell in July: Canopy Growth (CGC) and SNDL Inc. (SNDL)

Although the cannabis industry shows long-term growth potential, its near-term performance is hampered by intense regulations and limited financing. So, let's analyze whether you should Buy, Hold or Sell cannabis stocks SNDL (SNDL) and Canopy Growth (CGC).

StockNews.com

Is Canopy Growth (CGC) a Buy Under $2?

Canadian cannabis producer Canopy Growth (CGC) is making significant changes to its business model in an effort to turn profitable. However, given the regulatory challenges, will the company get success anytime soon? Let’s look at some of CGC’s metrics to understand if this penny stock is worth buying now.

StockNews.com

Conservatives Pushing 'Common Good Capitalism' Sound a Lot Like Progressives

The ideology champions the same tired policies that big government types predictably propose whenever they see something they don't like.

Reason

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Sell the Farm on These 4 Cannabis Stocks

Despite significant growth in recent years driven by increased legalization, the cannabis industry took a hit last year amid economic and industry-wide headwinds, including stubborn supply gluts. Furthermore, the industry will likely remain under pressure this year due to economic challenges. Hence, it could be wise to avoid fundamentally weak…

StockNews.com

3 Cannabis Stocks to Avoid Like the Plague in March 2023

The cannabis industry faced several challenges last year, including overproduction amid high inflation weighing on overall demand. With growing concerns over rising inflation and a looming recession, the industry is expected to remain under immense pressure this year. So, it could be wise to avoid fundamentally weak cannabis stocks Tilray…

StockNews.com

Marijuana Stocks: Buy or Sell These 3 in 2023?

Although several states have legalized marijuana, the industry faces a supply glut amid high inflation impacting overall demand. With Federal legalization unlikely this year, marijuana stocks could remain under pressure. Therefore, would it be wise to invest in marijuana stocks Tilray Brands (TLRY), Canopy Growth (CGC), and Aurora Cannabis (ACB)…

StockNews.com

2 Marijuana Stocks to Sell Short, Liquidate or Avoid in 2023

The marijuana industry took a hit facing economic challenges. With no immediate hope of federal legalization, it may be a while until the U.S. government looks favorably toward pot stocks. Hence, fundamentally weak marijuana stocks Tilray Brands (TLRY) and Canopy Growth (CGC) might be best avoided this year. Continue reading….

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

4 Marijuana Stocks to Avoid Like the Plague

While marijuana legalization has been rising, the industry is witnessing increased regulations. Moreover, the sector’s revenues have been declining recently. Hence, marijuana stocks Tilray Brands (TLRY), Canopy Growth (CGC), Sundial Growers (SNDL), and Aurora Cannabis (ACB) might be best avoided, given their weak fundamentals and negative profit margins. Keep reading.

Benzinga

Acreage Holdings: Analyst Increases Price Target To $1.44 And Remains Neutral

Acreage Holdings, Inc. (OTCQX: ACRDF) reported its financial results on Monday for the third quarter that ended September 30, 2022 (“Q3 2022”).

Benzinga

Jim Cramer Is Bullish On Cannabis Stocks Ahead Of Midterm Elections: 'I Say Buy Tilray'

Mad Money host Jim Cramer said last week during a Lightning Round segment that now is a good time to invest in Tilray.

StockNews.com

2 Marijuana Stocks That Are Nothing Short of Buzzkill

While the cannabis industry might be looking at a possible reversal of fortunes due to increased legalization for recreational and proven medicinal usage, fundamentally weak and beaten-down Marijuana stocks Tilray Brands (TLRY) and Canopy Growth (CGC) may be wealth destroyers. So, it could be wise for investors to avoid these…

Benzinga

Forget About SAFE Plus Or CLIMB Act As Cannabis Stock Catalysts, With Canopy's Potential Exception

Canopy Growth Corporation (NASDAQ: CGC)

Benzinga

This Is How It's Done: Why Is Canopy's US Consolidation Plan Blueprint For Other Canadian Cannabis LPs

Canadian cannabis giant Canopy Growth Corporation (NASDAQ: CGC) (TSX:WEED) announced its intention to consolidate in the US via a new holding company dubbed Canopy

StockNews.com

3 Cannabis Stocks Going up in Flames to Avoid

The wide use of cannabis for recreational activities and its increased medicinal use has helped the market gain traction over the past years. However, with legalization barriers worldwide, this industry is in an odd limbo in which consumption flourishes, but penalties and taxes still prevail. Given the backdrop, it should…

1 2 3

People

Kritika SarmahHer

727 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical – Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.